Dilsher S. Dhoot

1 week ago | ophthalmologytimes.com | Dilsher S. Dhoot |Mark R. Barakat |Martin Harp |Hattie Hayes

At ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg versus 2 mg during the matched dosing phase, and outcomes of shortened, maintained, or extended dosing intervalsEditor's note: The below transcript has been lightly edited for clarity. Hi, I'm here at ARVO 2025, and I'm presenting a poster for EYLEA HD and looking specifically at the PHOTON data. This is a post-hoc analysis.

1 month ago | optometrytimes.com | Dilsher S. Dhoot |Emily Kaiser Maharjan |Hattie Hayes

At the 2025 Controversies in Modern Eye Care conference, Dilsher Dhoot, MD, FASRS, of California Retina Consultants shared his forward-looking perspective on developments in retinal disease management, highlighting both recent breakthroughs and promising innovations on the horizon. The Controversies in Modern Eye Care meeting took place on May 4, 2025, in Los Angeles, California. GA management is evolving: New therapies exist, and more are coming with enhanced durability and efficacy.